These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 8895185)

  • 1. Animal models of the eosinophilia-myalgia syndrome.
    Clauw DJ
    J Rheumatol Suppl; 1996 Oct; 46():93-7; discussion 92, 97-8. PubMed ID: 8895185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bias or biology: evaluating the epidemiologic studies of L-tryptophan and the eosinophilia-myalgia syndrome.
    Horwitz RI; Daniels SR
    J Rheumatol Suppl; 1996 Oct; 46():60-72. PubMed ID: 8895182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiologic studies of the association of L-tryptophan with the eosinophilia-myalgia syndrome: a critique.
    Shapiro S
    J Rheumatol Suppl; 1996 Oct; 46():44-58; discussion 58-9. PubMed ID: 8895181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of L-tryptophan and eosinophilia-myalgia syndrome.
    Roufs JB
    J Am Diet Assoc; 1992 Jul; 92(7):844-50. PubMed ID: 1624654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A murine model of the eosinophilia-myalgia syndrome induced by 1,1'-ethylidenebis (L-tryptophan).
    Silver RM; Ludwicka A; Hampton M; Ohba T; Bingel SA; Smith T; Harley RA; Maize J; Heyes MP
    J Clin Invest; 1994 Apr; 93(4):1473-80. PubMed ID: 8163652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tryptophan produced by Showa Denko and epidemic eosinophilia-myalgia syndrome.
    Kilbourne EM; Philen RM; Kamb ML; Falk H
    J Rheumatol Suppl; 1996 Oct; 46():81-8; discussion 89-91. PubMed ID: 8895184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for developing eosinophilia myalgia syndrome among L-tryptophan users in New York.
    Back EE; Henning KJ; Kallenbach LR; Brix KA; Gunn RA; Melius JM
    J Rheumatol; 1993 Apr; 20(4):666-72. PubMed ID: 8496862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1,1'-Ethylidenebis[L-tryptophan], an impurity in L-tryptophan associated with eosinophilia-myalgia syndrome, stimulates type I collagen gene expression in human fibroblasts in vitro.
    Zangrilli JG; Mayeno AN; Vining V; Varga J
    Biochem Mol Biol Int; 1995 Nov; 37(5):925-33. PubMed ID: 8624499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A case of the eosinophilia-myalgia syndrome].
    Ishikawa A; Akahosi T; Okada J; Kondo H; Kasiwazaki S
    Ryumachi; 1992 Aug; 32(4):327-30; discussion 330-2. PubMed ID: 1411794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eosinophilia-myalgia syndrome among the non-L-tryptophan users and pre-epidemic cases.
    Sullivan EA; Staehling N; Philen RM
    J Rheumatol; 1996 Oct; 23(10):1784-7. PubMed ID: 8895159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L-tryptophan implicated in human eosinophilia-myalgia syndrome causes fasciitis and perimyositis in the Lewis rat.
    Crofford LJ; Rader JI; Dalakas MC; Hill RH; Page SW; Needham LL; Brady LS; Heyes MP; Wilder RL; Gold PW
    J Clin Invest; 1990 Nov; 86(5):1757-63. PubMed ID: 2243145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tryptophan contaminants associated with eosinophilia-myalgia syndrome. The Eosinophilia-Myalgia Studies of Oregon, New York and New Mexico.
    Philen RM; Hill RH; Flanders WD; Caudill SP; Needham L; Sewell L; Sampson EJ; Falk H; Kilbourne EM
    Am J Epidemiol; 1993 Aug; 138(3):154-9. PubMed ID: 8356958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A contaminant of L-tryptophan enhances expression of dermal collagen in a murine model of eosinophilia myalgia syndrome.
    Suzuki S; Tourkina E; Ludwicka A; Hampton M; Bolster M; Maize J; Silver R
    Proc Assoc Am Physicians; 1996 Jul; 108(4):315-22. PubMed ID: 8863345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Demyelinating polyneuropathy in eosinophilia-myalgia syndrome.
    Donofrio PD; Stanton C; Miller VS; Oestreich L; Lefkowitz DS; Walker FO; Ely EW
    Muscle Nerve; 1992 Jul; 15(7):796-805. PubMed ID: 1323757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology of potential association between L-tryptophan ingestion and eosinophilia-myalgia syndrome.
    Daniels SR; Hudson JI; Horwitz RI
    J Clin Epidemiol; 1995 Dec; 48(12):1413-27; discussion 1429-40. PubMed ID: 8543957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eosinophilia-myalgia syndrome: a recent syndrome serving as an alert to new diseases ahead.
    Sidransky H
    Mod Pathol; 1994 Sep; 7(7):806-10. PubMed ID: 7824518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Eosinophilia-myalgia syndrome].
    Kotake S; Kashiwazaki S
    Nihon Rinsho; 1992 Jul; 50(7):1650-5. PubMed ID: 1404896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contaminants in L-tryptophan associated with eosinophilia myalgia syndrome.
    Hill RH; Caudill SP; Philen RM; Bailey SL; Flanders WD; Driskell WJ; Kamb ML; Needham LL; Sampson EJ
    Arch Environ Contam Toxicol; 1993 Jul; 25(1):134-42. PubMed ID: 8346973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic bias in clinical decision making: an example of L-tryptophan and the diagnosis of eosinophilia-myalgia syndrome.
    Wagner KR; Elmore JG; Horwitz RI
    J Rheumatol; 1996 Dec; 23(12):2079-85. PubMed ID: 8970044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upper extremity contractures in a patient with eosinophilia-myalgia syndrome.
    Marchman HB; Gleason CB; Shaw JC
    Arch Phys Med Rehabil; 1991 Nov; 72(12):1029-30. PubMed ID: 1953317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.